Discover how Novo Nordisk's pipeline is being restructured to refocus its efforts on high-growth areas like diabetes and ...

Pedersen, Maggie Fick and Bhanvi Satija COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year profit and ...

As Novo Nordisk and Pfizer fight over a promising GLP-1 pipeline at Metsera, Amgen is staying the course on its ...

Novo Nordisk has lowered its full-year profit and sales forecasts amid slowed sales growth. However, a better-than-expected ...

Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues ...

Novo Nordisk is winding down a range of early-stage programs for liver disease, oncology and stem cells as part of the Danish ...

Novo Nordisk Q3 profit drops on restructuring costs as GLP-1 and obesity drug sales rise; company narrows 2025 growth outlook.

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk lowered its full-year profit and sales forecasts again on Wednesday, in an ...

Another quarterly earnings announcement from Novo Nordisk and another downgrade to earnings guidance from the Danish ...

Earlier in the day, Novo Nordisk announced that it raised its acquisition bid to acquire Metsera, Inc. (NASDAQ:MTSR) for $10 ...

Novo Nordisk's new CEO said he was confident in the company's pipeline of obesity drugs, but that buying Metsera would allow ...